Teladoc Health, Inc. · NYSE:TDOC
Teladoc Health — Investor Presentation (January 2018)
22 slides from Teladoc Health's investor presentation, Jan 8, 2018
Slide 1: Safe Harbor Statement
Safe Harbor Statement This presentation contains, and our officers may make, “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. These forward-looking statements include, without limitation, information concern
Slide 2: Leading the Way in Virtual Care Delivery
Leading the Way in Virtual Care Delivery At Teladoc, we are transforming how people access healthcare globally. We provide a new kind of healthcare experience: one with better convenience, outcomes and value. At Teladoc, we are transforming how people access healthcare globally. We provide a new kin
Slide 3: Company Highlights
Expert Opinion based on total annual U.S. incidence of Cancer (American Cancer Society), Epilepsy (Epilepsy Foundation), MS (Multiple Sclerosis Foundation), IBD/Crohn’s/Colitis (Crohn’s and Colitis Foundation), Diverticulitis (Gastroenterology and Hepatology), Rheumatoid Arthritis (Best Practices &
Slide 4: Teladoc at a Glance
Teladoc at a Glance Members (M) Revenue (M) Visits (K) PEPM Highlights 74% Revenue CAGR (2014-2017E) 10,000+ Total Clients 300+ Fortune 1000 Clients 35+ Health Plan Clients 200+ Hospitals & Health Systems 73% CAGR 37% CAGR 34% CAGR 57% CAGR Note: Presented as reported. Full-year Management Guidance;
Slide 5: Execution on Growth Strategy
Execution on Growth Strategy Purple: 94-13-139 Dark blue: 0-102-160 New Accounts & Channels Existing Health Plans Increase Utilization Direct to Consumer International Behavioral Health Dermatology Expert Opinion & Specialty Advice STI / HIV Testing Diabetes Health Kiosk Mobile Apps / Hubs Biometric
Slide 6: Teladoc TAM Expansion & Significant Penetration Opportunity
Teladoc TAM Expansion & Significant Penetration Opportunity (1) Expert Opinion based on total annual U.S. incidence of Cancer (American Cancer Society), Epilepsy (Epilepsy Foundation), MS (Multiple Sclerosis Foundation), IBD/Crohn’s/Colitis (Crohn’s and Colitis Foundation), Diverticulitis (Gastroent
Slide 7: Broad Client Base and Distribution
Broad Client Base and Distribution 10,000+ clients including 300+ of Fortune 1000 companies 35+ Fully-Insured and ASO Health Plans Employers (Direct and via Brokers) 200+ Hospitals / Health Systems Selective DTC Global Financial Services 8
Slide 8: Redefined Competitive Landscape
Redefined Competitive Landscape Single Market Diversified Distribution Second Opinion Virtual Urgent Care Competitor G Competitor F Competitor A Competitor B Competitor E Competitor C Competitor D Full Continuum of Care Point Solution Note: Competitor information represents Teladoc management estima
Slide 9: Macro Trends Align with Telehealth Adoption
Macro Trends Align with Telehealth Adoption (1) ComScore, 2016 (2) National Business Group on Health, 2016 (3) American Telemedicine Association, 2016 Purple: 94-13-139 Dark blue: 0-102-160 Visits growing faster than membership driven by consumer engagement efforts Teladoc is at a Key Inflection Poi
Slide 10: "Surround Sound" Member Engagement Strategy Yields Tailwinds from Installed Base
“Surround Sound” Member Engagement Strategy Yields Tailwinds from Installed Base Purple: 94-13-139 Dark blue: 0-102-160 (1) Cohort by calendar year refers to membership base associated with clients on-boarded in given calendar year. Represents clients with 50K or fewer U.S. Paid Members. Top of mind
Slide 11: What is Best Doctors?
What is Best Doctors? (1) Represent total book of business. Changes to diagnoses and treatment plan vary by condition. Purple: 94-13-139 Dark blue: 0-102-160 Best Doctors identifies and solves the most complex, critical, and costly problems in health care by combining data analytics and top clinical
Slide 12: Solving the Most Complex & Costliest Cases
Solving the Most Complex & Costliest Cases 13 3% 20% 77% 37% 40% 23% Episodic Care Chronic Care Critical Care Percent of Cost $472: Avg. claims savings / visit $36K: Avg. savings / expert review $116K: Avg. savings / critical care case Percent of Population $46: Avg. productivity savings / visit
Slide 13: Realizing Our Integrated Offering
Built new dedicated Best Doctors mobile app Integrated TD and BD single solution – mobile/web Launched integrated experience – ahead of schedule! Realizing Our Integrated Offering Access Measuring Success Increase revenue per Member & Visit Positive utilization New clients, expanded channels Strong
Slide 14: Building a Virtual Healthcare Ecosystem Through Product Portfolio Expansion
Building a Virtual Healthcare Ecosystem Through Product Portfolio Expansion 15 Volume Complexity, Cost Higher Lower My child woke up this morning with a fever I want to address my anxiety I need help managing my high blood pressure Is this the best treatment plan for my cancer? My husband just recei
Slide 15: Cross-Selling Integrated Solution
20+ wins representing several million dollars of revenue Cross-Selling Integrated Solution Early wins and future opportunities 200m+ figure calculated as (BD U.S. Paid Members without Teladoc access X average Teladoc PEPM) + (Teladoc U.S. Paid Members without Best Doctors access X average Best Docto
Slide 16: New Business Wins
New Business Wins Momentum across broad spectrum of large partnerships 17
Slide 17: Teladoc: Proven Scalable Results
Visits in busiest month (K) Visits in busiest hour Visits (000s) Median response time in busiest month Visits in busiest day 72% CAGR 64% CAGR 84% CAGR 18 Teladoc : Proven Scalable Results 2,941 5,247 8,720 2015 2016 2017 73 126 196 2015 2016 2017 311 459 1,056 2015 2016 2017 8:14 11:10 9:43 2015 20
Slide 18: Q4 2017 Guidance vs Actual (Unaudited)
Q4 2017 Guidance Q4 2017 Actual (Unaudited) ~$75 – $77 million ~103% y-o-y growth $76 – $77 million ~103% y-o-y growth Revenue ~$1 – $2 million ~119%+ y-o-y growth ~$2 – $3 million ~131% y-o-y growth Adjusted EBITDA ~400K – 450K Visits ~37%+ y-o-y growth ~ 460K Visits ~48% y-o-y growth Total Visits
Slide 19: 2017 Actual and 2018 Outlook
2017 Actual (Unaudited) 2018 Outlook ~$232 – $233 million ~88% y-o-y growth $350 – $360 million ~52% y-o-y growth Revenue ~$(12) – $(13) million ~67%+ y-o-y growth $7 – $10 million ~169% y-o-y growth Adjusted EBITDA ~1,460K Visits ~53%+ y-o-y growth 1,900K – 2,000K Visits ~33% y-o-y growth Total Vis
Slide 20: Teladoc Balance Sheet
Teladoc Balance Sheet Liquidity as of 12/31/17 Debt as of 12/31/17 Balance sheet has been deleveraged with the December 8, 2017 repayment of all Senior Debt Debt covenants have accordingly been removed Income statement and cash flow profile enhanced with the elimination of >$15mm in annual interest
Slide 21: Execution on Growth Strategy
Execution on Growth Strategy Purple: 94-13-139 Dark blue: 0-102-160 New Accounts & Channels Existing Health Plans Increase Utilization Direct to Consumer International Behavioral Health Dermatology Expert Opinion & Specialty Advice STI / HIV Testing Diabetes Health Kiosk Mobile Apps / Hubs Biometric
Slide 22: Execution on Growth Strategy
Execution on Growth Strategy Expand Footprint & Penetration Expand Specialties v New Accounts & Channels vi Behavioral Health v Existing Health Plans Wo Dermatology Vo Wrerease Utlzation Expert Opinion & Specialty Advice o/ Direct to Consumer vv STI/ HIV Testing of Werationl Diabetes Expand Scope of